Septerna (NASDAQ:SEPN) Trading Up 6.7% – Here’s What Happened

Septerna, Inc. (NASDAQ:SEPN) was up 6.7% during mid-day trading on Wednesday . The company traded as high as $23.10 and last traded at $23.1540. Approximately 99,459 shares changed hands during trading, a decline of 83% from the average daily volume of 573,105 shares. The stock had previously closed at $21.69.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on SEPN shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $25.00 price objective on shares of Septerna in a report on Friday, September 5th. HC Wainwright upped their price target on Septerna from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Wall Street Zen upgraded shares of Septerna from a “sell” rating to a “buy” rating in a report on Sunday, November 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company upgraded shares of Septerna from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $18.00 to $28.00 in a report on Friday, November 14th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Septerna has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

Septerna Price Performance

The firm has a market cap of $1.14 billion and a price-to-earnings ratio of -16.93. The company’s 50 day simple moving average is $19.97 and its 200 day simple moving average is $14.19.

Septerna (NASDAQ:SEPN) last released its earnings results on Monday, November 10th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.19 by ($0.28). The company had revenue of $21.50 million for the quarter, compared to analyst estimates of $24.50 million. Septerna had a negative return on equity of 17.98% and a negative net margin of 266.77%. As a group, analysts forecast that Septerna, Inc. will post -7.11 earnings per share for the current year.

Insider Buying and Selling

In other Septerna news, SVP Daniel D. Long sold 3,501 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $18.06, for a total value of $63,228.06. Following the sale, the senior vice president directly owned 92,911 shares of the company’s stock, valued at approximately $1,677,972.66. This represents a 3.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 4.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Nuveen LLC acquired a new stake in shares of Septerna during the 1st quarter worth about $139,000. Checkpoint Capital L.P. purchased a new position in Septerna in the first quarter valued at approximately $4,776,000. ADAR1 Capital Management LLC purchased a new position in Septerna in the first quarter valued at approximately $4,174,000. Swiss National Bank acquired a new stake in Septerna during the first quarter worth approximately $174,000. Finally, BVF Inc. IL lifted its position in shares of Septerna by 79.3% during the 1st quarter. BVF Inc. IL now owns 4,396,124 shares of the company’s stock worth $25,454,000 after buying an additional 1,944,100 shares during the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.